Avidity Biosciences (Avidity Biosciences) FCF Yield % : -5.31 (As of May. 01, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Avidity Biosciences FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Avidity Biosciences's Trailing 12-Month Free Cash Flow is $-123.29 Mil, and Market Cap is $2,320.65 Mil. Therefore, Avidity Biosciences's FCF Yield % for today is -5.31%.

The historical rank and industry rank for Avidity Biosciences's FCF Yield % or its related term are showing as below:

RNA' s FCF Yield % Range Over the Past 10 Years
Min: -49.6 Med: -11.17 Max: -0.28
Current: -5.31

During the past 6 years, the highest FCF Yield % of Avidity Biosciences was -0.28%. The lowest was -49.60%. And the median was -11.17%.

RNA's FCF Yield % is ranked better than
66.69% of 1552 companies
in the Biotechnology industry
Industry Median: -14.81 vs RNA: -5.31

Avidity Biosciences's FCF Margin % for the quarter that ended in Dec. 2023 was 713.09%.

Avidity Biosciences FCF Yield % Historical Data

The historical data trend for Avidity Biosciences's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avidity Biosciences FCF Yield % Chart

Avidity Biosciences Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Yield %

Get a 7-Day Free Trial

-3.99

-8.68

-8.98

-17.19

Avidity Biosciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Yield %	Get a 7-Day Free Trial															-10.34	-18.69	-24.56	-31.91	8.72

Competitive Comparison of Avidity Biosciences's FCF Yield %

For the Biotechnology subindustry, Avidity Biosciences's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Avidity Biosciences's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avidity Biosciences's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Avidity Biosciences's FCF Yield % falls into.

Avidity Biosciences FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Avidity Biosciences's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-123.292	/	717.43875
	=	-17.19%

Avidity Biosciences's annualized FCF Yield % for the quarter that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	15.638	*	4	/	717.43875
	=	8.72%

Avidity Biosciences FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Avidity Biosciences FCF Yield % Related Terms

Thank you for viewing the detailed overview of Avidity Biosciences's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Avidity Biosciences (Avidity Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avidity Biosciences Inc (NAS:RNA) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

10578 Science Center Drive, Suite 125, San Diego, CA, USA, 92121

Website

https://www.aviditybiosciences.com

Avidity Biosciences Inc is a biotechnology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Its product, AOC 1001, is designed to treat a rare monogenic muscle disease.

Executives

Michael F Maclean	officer: Chief Financial Officer	14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
W. Michael Flanagan	officer: Chief Technical Officer	C/O AVIDITY BIOSCIENCES, INC., 10975 N. TORREY PINES RD., SUITE 150, LA JOLLA CA 92037
Teresa Mccarthy	officer: Chief Human Resources Officer	10975 N TORREY PINES RD #150, LA JOLLA CA 92037
Arthur A Levin	officer: Chief Scientific Officer	1896 RUTHERFORD ROAD, CARLSBAD CA 92008
Sarah Boyce	director, officer: President and CEO	C/O IONIS PHARMACEUTICALS, INC., 2855 GAZELLE COURT, CARLSBAD CA 92010
Eric Mosbrooker	director	C/O HORIZON PHARMA, PLC, ADELAIDE CHAMBERS, PETER STREET, DUBLIN 8 L2 000000
Rtw Investments, Lp	10 percent owner	40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Jean Jinsun Kim	director	C/O AVIDITY BIOSCIENCES, INC., 10975 N. TORREY PINES RD., SUITE 150, LA JOLLA CA 92037
Tamar Thompson	director	C/O AVIDITY BIOSCIENCES, INC., 10975 N. TORREY PINES RD., SUITE 150, LA JOLLA CA 92037
Jae B. Kim	officer: Chief Medical Officer	C/O AVIDITY BIOSCIENCES, INC., 10975 N. TORREY PINES RD., SUITE 150, LA JOLLA CA 92037
Cormorant Asset Management, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Noreen Henig	director	C/O KEZAR LIFE SCIENCES, INC., 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Lilly Eli & Co	10 percent owner	LILLY CORPORATE CENTER, DROP CODE 1094, INDIANAPOLIS IN 46285
Todd C Brady	director	C/O EVOKE PHARMA, INC., 505 LOMAS SANTA FE DRIVE, SOLANA BEACH CA 92075
Michael B. Martin	director	C/O AVIDITY BIOSCIENCES, INC., 10975 N. TORREY PINES RD., SUITE 150, LA JOLLA CA 92037